ECONOMIC COMPARISON OF THERAPEUTIC ALTERNATIVES FOR FIRSTLINE TREATMENT OF MULTIPLE MYELOMA

M.D. GIL-SIERRA¹, S. FENIX-CABALLERO¹, M.D.P. BRICEÑO-CASADO¹, M. DOMINGUEZ-CANTERO¹, E.J. ALEGRE-DEL REY¹.
¹HOSPITAL UNIVERSITARIO DE PUERTO REAL, PHARMACY, PUERTO REAL, SPAIN

AIM
To develop an economic comparison among therapeutic alternatives in NDMM

BACKGROUND

- Combination of daratumumab, bortezomib, melphalan and prednisone with daratumumab in maintenance (DVMP-D) has been authorized in first line of treatment for patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation (NDMM-NoT).
- It makes necessary an economic comparison among different alternatives available, according to their economic impact.

MATERIAL AND METHODS

- Bibliographic research in Medline and Embase
- Inclusion criteria: Treatment schemes: daratumumab, lenalidomide, bortezomib, thalidomide or combinations
- Authorized treatments used in clinical practice
- Randomized clinical trials phase II-III.
- Articles in Spanish or English.
- Efficacy: progression-free survival.

RESULTS

- Costs of the first-year treatment: Notified laboratory sale price + 4% VAT - 7.5% rebate (Royal Decree-Law 8/2010)
- Associated direct costs in first year:
  - Incremental costs with respect to reference: DVMP-D

<table>
<thead>
<tr>
<th>Drug Combination</th>
<th>Associated Direct Costs in First Year (€)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DVMP-D</td>
<td>184,214</td>
</tr>
<tr>
<td>Bortezomib+ melphalan+ Prednisone (VMP)</td>
<td>44,435</td>
</tr>
<tr>
<td>Melphalan+ Prednisone+ thalidomide with thalidomide in maintenance (MPT-T)</td>
<td>44,435</td>
</tr>
<tr>
<td>Lenalidomide+ dexamethasone in maintenance (RD)</td>
<td>81,520</td>
</tr>
<tr>
<td>Lenalidomide+ dexamethasone for 18 cycles (RD18)</td>
<td>81,520</td>
</tr>
<tr>
<td>Melphalan+ thalidomide+ prednisone (MTP)</td>
<td>77,209</td>
</tr>
<tr>
<td>Bortezomib+ lenalidomide+ dexamethasone with lenalidomide+ dexamethasone in maintenance (VRD-RD)</td>
<td>104,850</td>
</tr>
</tbody>
</table>

- Incremental costs

1. Most expensive scheme: DVMP-D
2. Most expensive: VRD-RD (-79,364€)

1. Cheapest scheme: MPT-T (-164,094€)
2. Cheapest: VMP (-139,779€)

CONCLUSION

1. There are 7 treatments including daratumumab, lenalidomide, bortezomib or thalidomide for NDMM-NoT. 2. The most expensive schemes for the first year of treatment are DVMP-D and VRD-RD; and the cheapest combinations are MPT-T and VMP.